A retrospective analysis of the efficacy and safety of immune combination therapy in driver gene-negative non-small cell lung cancer with brain metastases
Cancer Treatment and Research Communications · 2025
DOI: 10.1016/j.ctarc.2025.101015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Kuo Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of radiotherapy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Brain Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Medical and Health Science and Technology Development Project of Shandong Province, Wu Jieping Medical Foundation.
Abstract (Originalsprache)
PURPOSE: Central nervous system metastases, significantly worsen the prognosis of driver gene-negative non-small cell lung cancer (NSCLC) patients. This study aims to evaluate the efficacy and safety of immunotherapy in driver gene-negative NSCLC patients with brain metastases (BMs). METHOD: A retrospective analysis was conducted on 244 driver gene-negative NSCLC patients with BMs treated at Shandong Cancer Hospital between August 2019 and December 2023. Patients received immunotherapy (camrelizumab, tislelizumab, sintilimab, pembrolizumab) alone or in combination with radiotherapy. Efficacy endpoints included intracranial objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), assessed using RECIST 1.1 and RANO criteria. Statistical analyses were performed using Kaplan-Meier methods. RESULT: The intracranial ORR and DCR were 53.3 % and 89.4 %, respectively. The median PFS and OS were 18.0 and 49.0 months, with a 2-year OS rate of 78.8 %. Combined radiotherapy improved short-term PFS (17.0 vs. 21.0 months, P=0.265) but not OS (P=0.656). Camrelizumab demonstrated a superior median PFS (28.0 months) compared to other agents (P=0.0044). Concurrent radiotherapy timing yielded the highest survival outcomes (PFS: 18.0 months; OS: 59.0 months). CONCLUSION: Immunotherapy shows robust efficacy in driver gene-negative NSCLC with brain metastases, particularly for intracranial control. Camrelizumab outperformed other ICIs, and concurrent radiotherapy provided transient PFS benefits without OS improvement. These findings highlight the potential of immunotherapy as a cornerstone therapy, warranting further exploration of combination strategies and biomarker-driven approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of radiotherapy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
- Quality Management Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
- Department of Oncology, Zaozhuang City Hospital, Zaozhuang, Shandong Province, China.
- Jining First People's Hospital Jinjing, Jinjing, Shandong Province, China.
- Department of internal medicine, Qingdao Hiser Hospital Affiliated of Qingdao University, Qingdao Traditional Chinese Medicine Hospital, Qingdao, Shandong Province, China.
- Department of radiotherapy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. Electronic address: gmlhx@163.com.
Förderung
- National Natural Science Foundation of China
- Medical and Health Science and Technology Development Project of Shandong Province
- Wu Jieping Medical Foundation
Zitieren
APA
Li, K., Wang, B., Liu, S., Li, C., Cui, H., Qi, Z., Sun, G., Zheng, X., & Gao, M. (2025). A retrospective analysis of the efficacy and safety of immune combination therapy in driver gene-negative non-small cell lung cancer with brain metastases. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.101015
Vancouver
Li K, Wang B, Liu S, Li C, Cui H, Qi Z, et al. A retrospective analysis of the efficacy and safety of immune combination therapy in driver gene-negative non-small cell lung cancer with brain metastases. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.101015
BibTeX
@article{Li2025,
author = {Li, Kuo and Wang, Bingxiang and Liu, Shuaishuai and Li, Cheng and Cui, Hongxia and Qi, Zhenli and Sun, Guanxing and Zheng, Xin and Gao, Min},
title = {A retrospective analysis of the efficacy and safety of immune combination therapy in driver gene-negative non-small cell lung cancer with brain metastases},
journal = {Cancer Treatment and Research Communications},
year = {2025},
doi = {10.1016/j.ctarc.2025.101015}
}
EUVIMED